Blog / Archives
Biotech Movers du jour: Biogen (BIIB), Cubist(CBST), Nektar (NKTR)
Biogen(BIIB $103) soared 19% today reporting profit of $294.3M EPS of $1.20 compared to $217.4 and EPS of 0.80 in the previous year. Revenue from its drug Tysabri used to treat Crohn's and MS grew...
Tech Leads Biotech Sector Higher, But Amgen (AMGN) and Gilead (GILD) Weak After Earnings
Tech Goes from Laggard to Leader Taking Strong Biotech Sector Along for the Ride Tech stocks rallied big today with the NASDAQ up 2.1% to 2802, The Dow hit a new 2 1/2 year high up 1.5% to...
Lackluster Trading In Biotech:Sell-Off Continues In Smaller Caps
Markets stabilized today with major indices up in the 0.4% range. Despite some weakness in meteoric biopharma stocks the healthcare sector is catching bids. Unloved and unwanted Johnson and...
Biotech Rally Ends With S&P Negative Outlook;But Amarin (AMRN) Soars
Even the biotech bulls bailed today on the double whammy of concern about Europe's debt crisis and the S&P echoing the Tea Party refrain about the U.S. budget deficit and need for fiscal reform....
Biotech Stocks Roll Merrily Along Up 1%+
Drug and Biotechnology Stocks Up Across the Spectrum Its "groundhog day" in biotech world. Apparently money that has come out of tech stocks and money markets is going into healthcare stocks. In...
Biggest Biotech Trends
This was published today on www.InvestorUprising.com. Biotech stocks are up 10% YTD. Investor Uprising - Rod Raynovich - The Biggest Biotech Trends
Biotech Sector Outperforming Within NASDAQ: Dendreon(DNDN),Idenix(IDIX) and Viropharma(VPHM) Soar
Biotech stocks are up again today ignoring the overall weakness in tech stocks. Among the notable movers today are: Dendreon (DNDN $41.15) broke out above 40 up 5.5% on heavy volume with high...
Life Science Market Update: Risk Off, Raise Cash
Biotechnology Sector Outperforming Within NASDAQ A torrid run-up of over 10% in biotech stocks over the past 3 weeks brings caution to mind as the NASDAQ sell-off hits 1%. Over the past 5 days the...
Rayno Life Science Portfolio: Exelixis Up 10% Pre-Market On Takeover Talk
Exelixis (EXEL $12.17) has hired Goldman-Sachs to deal with potential takeover bids according to stories in Reuters and Bloomberg. Exelixis has a Phase III cancer drug XL184 (cabozantinab) and...
Rayno Life Science Portfolio: Biogen (BIIB) up 6.6 % on Positive MS Data
Biogen (BIIB $78.24) soared today on positive top line data on the Phase 3 Trial for oral BG-12 (dimethyl fumarate) as a montherapy in people with relapsing-remitting multiple sclerosis (RRMS)....